Corrigendum

Authors

  • D. Russo,

  • M. Malagola


The authors of Russo et al (2005) would like to make a correction on their paper entitled ‘Multicenter phase III trial on fludarabine, Ara-C, and idarubicine (FLAI) versus idarubicine, Ara-C and etoposide (ICE) for induction treatment of younger newly diagnosed acute myeloid leukaemia patients’ recently published. In Table 2 (page 175) the correct number of patients eligible for intensification in the FLAI arm was 41 out of 57 (72%), instead of 41 out of 46 (89%) and the difference between the proportion of patients eligible for intensification in the FLAI arm and the proportion of patients eligible for intensification in the ICE arm was not statistically significant (P = 0 · 09). More properly, the correct sentence in the discussion (page 177, line 27) is ‘The patients who were eligible for intensification with auto or allo-SCT in FLAI arm were more than those who were eligible in the ICE arm [41/57 (72%) in FLAI arm vs. 31/55 (56%) in ICE arm; P =  0 · 09]’.

Ancillary